Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D.

Calcitriol, the hormonally active form of vitamin D, is being evaluated in clinical trials as an anti-cancer agent. Calcitriol exerts multiple anti-proliferative, pro-apoptotic, and pro-differentiating actions on various malignant cells and retards tumor growth in animal models of cancer. Calcitriol also exhibits several anti-inflammatory effects including suppression of prostaglandin (PG) action, inhibition of p38 stress kinase signaling, and the subsequent production of pro-inflammatory cytokines and inhibition of NF-κB signaling. Calcitriol also decreases the expression of aromatase, the enzyme that catalyzes estrogen synthesis in breast cancer, both by a direct transcriptional repression and indirectly by reducing PGs, which are major stimulators of aromatase transcription. Other important effects include the suppression of tumor angiogenesis, invasion, and metastasis. These calcitriol actions provide a basis for its potential use in cancer therapy and chemoprevention. We summarize the status of trials involving calcitriol and its analogs, used alone or in combination with known anti-cancer agents.

[1]  D. Trump,et al.  The role of vitamin D in cancer prevention and treatment. , 2012, Rheumatic diseases clinics of North America.

[2]  M. Grossbard,et al.  Vitamin D and breast cancer. , 2012, The oncologist.

[3]  C. Davis,et al.  Vitamin D and colon cancer , 2011, Expert review of gastroenterology & hepatology.

[4]  D. Feldman,et al.  Anti-inflammatory Activity of Calcitriol in Cancer , 2011 .

[5]  C. Mathieu,et al.  Vitamin D: a pleiotropic hormone. , 2010, Kidney international.

[6]  M. Holick Vitamin D: Physiology, Molecular Biology, and Clinical Applications , 2010 .

[7]  L. Raisz,et al.  Prostaglandins in bone: bad cop, good cop? , 2010, Trends in Endocrinology & Metabolism.

[8]  K. Knudsen,et al.  Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer , 2010, Trends in Endocrinology & Metabolism.

[9]  N. Weigel,et al.  1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. , 2010, Endocrinology.

[10]  D. Feldman,et al.  Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. , 2010, Endocrine-related cancer.

[11]  K. Knudsen,et al.  Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. , 2010, Endocrinology.

[12]  J. Adams,et al.  Update in vitamin D. , 2010, The Journal of clinical endocrinology and metabolism.

[13]  G. Dranitsaris,et al.  A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases , 2010, Cancer.

[14]  D. Trump,et al.  Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and Therapy , 2010, Cancer journal.

[15]  D. Feldman,et al.  Anti-inflammatory Activity of Calcitriol That Contributes to Its Therapeutic and Chemopreventive Effects in Prostate Cancer , 2010 .

[16]  S. Srinivas,et al.  A phase II trial of calcitriol and naproxen in recurrent prostate cancer. , 2009, Anticancer research.

[17]  D. Feldman,et al.  Unraveling insulin-like growth factor binding protein-3 actions in human disease. , 2009, Endocrine reviews.

[18]  Sam S. Chang,et al.  Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. , 2009, The Journal of urology.

[19]  N. Weigel,et al.  1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. , 2009, Endocrinology.

[20]  H. Bischoff-Ferrari Vitamin D in Fracture Prevention and Muscle Function and Fall Prevention , 2009 .

[21]  S. Gümüşlü,et al.  Cyclooxygenase-2 in Cancer and Angiogenesis , 2009, Angiology.

[22]  Bryan M. Gillard,et al.  Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. , 2009, Cancer research.

[23]  S. Srinivas,et al.  Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer , 2009, Dermato-endocrinology.

[24]  Jining Wang,et al.  Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer Therapy. , 2009, Endocrine reviews.

[25]  F. Fulfaro,et al.  Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C , 2009, Medical oncology.

[26]  D. Bikle Nonclassic actions of vitamin D. , 2009, The Journal of clinical endocrinology and metabolism.

[27]  J. Pinski,et al.  A phase II study of high‐dose calcitriol combined with mitoxantrone and prednisone for androgen‐independent prostate cancer , 2008, BJU international.

[28]  E. Giovannucci,et al.  Vitamin D and Prevention of Colorectal Adenoma: A Meta-analysis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[29]  A. Muñoz,et al.  Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. , 2008, Anticancer research.

[30]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[31]  J. Meyerhardt,et al.  Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Nilanjan Chatterjee,et al.  Serum vitamin D concentration and prostate cancer risk: a nested case-control study. , 2008, Journal of the National Cancer Institute.

[33]  Masao Omata,et al.  Inflammation and cancer: Role of nuclear factor‐kappaB activation , 2008, Cancer science.

[34]  D. McNeel,et al.  Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[35]  E. Rankin,et al.  The role of hypoxia-inducible factors in tumorigenesis , 2008, Cell Death and Differentiation.

[36]  N. Kyprianou,et al.  Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance , 2008, Journal of cellular biochemistry.

[37]  P. Allavena,et al.  Pathways connecting inflammation and cancer. , 2008, Current opinion in genetics & development.

[38]  W. Fawzi,et al.  Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial , 2007, International journal of cancer.

[39]  R. Mehta,et al.  25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture , 2008, Breast Cancer Research and Treatment.

[40]  E. Balint,et al.  CHAPTER 13 – Vitamin D: Biology, Action, and Clinical Implications , 2008 .

[41]  Long Wang,et al.  Chronic inflammation in benign prostatic hyperplasia: implications for therapy. , 2008, Medical hypotheses.

[42]  E. Giovannucci Vitamin D status and cancer incidence and mortality. , 2008, Advances in experimental medicine and biology.

[43]  S. Ingles,et al.  Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. , 2007, American journal of epidemiology.

[44]  J. Welsh Targets of Vitamin D Receptor Signaling in the Mammary Gland , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  D. Peehl,et al.  Calcitriol as a Chemopreventive and Therapeutic Agent in Prostate Cancer: Role of Anti‐Inflammatory Activity , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  G. Francini,et al.  Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel , 2007, BJU international.

[47]  Z. Tulassay,et al.  Carcinogenesis in Inflammatory Bowel Disease , 2007, Digestive Diseases.

[48]  D. Trump Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators , 2007 .

[49]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[50]  N. Weigel Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. , 2007, Nutrition reviews.

[51]  J. Welsh,et al.  Calcium, vitamin D and the vitamin D receptor: impact on prostate and breast cancer in preclinical models. , 2007, Nutrition reviews.

[52]  Louise R Howe,et al.  Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer , 2007, Breast Cancer Research.

[53]  M. Schwab,et al.  Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. , 2007, Molecular immunology.

[54]  D. S. St. Clair,et al.  Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1α,25-dihydroxyvitamin D3 in prostate cancer cells , 2007, Molecular Cancer Therapeutics.

[55]  S. Markowitz Aspirin and colon cancer--targeting prevention? , 2007, The New England journal of medicine.

[56]  L. Mosekilde,et al.  [Vitamin D and breast cancer]. , 2007, Ugeskrift for laeger.

[57]  D. Dang,et al.  1α,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells , 2007, Molecular Cancer Therapeutics.

[58]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[59]  E. Giovannucci,et al.  Vitamin D and prevention of breast cancer: Pooled analysis , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[60]  A. Bonanomi,et al.  The Vitamin D analogue TX 527 blocks NF-κB activation in peripheral blood mononuclear cells of patients with Crohn's disease , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[61]  G. Schwartz,et al.  Vitamin D status and cancer: new insights , 2007, Current opinion in clinical nutrition and metabolic care.

[62]  D. Dang,et al.  1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. , 2007, Molecular cancer therapeutics.

[63]  S. Rose-John,et al.  Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[64]  C. Mathieu,et al.  Vitamin D and cancer , 2013, Cell cycle.

[65]  Melissa L. Johnson,et al.  Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. , 2006, Seminars in oncology.

[66]  A. Whittemore,et al.  Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States) , 2006, Cancer Causes & Control.

[67]  C. Ryan,et al.  High dose calcitriol may reduce thrombosis in cancer patients , 2006, British journal of haematology.

[68]  R. DiPaola,et al.  Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1; Pten Mutant Mice , 2006, Clinical Cancer Research.

[69]  Jorge Yao,et al.  1 a , 25-dihydroxyvitamin D 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis , 2006 .

[70]  Brian L. Cohen,et al.  Cyclooxygenase‐2 (cox‐2) expression is an independent predictor of prostate cancer recurrence , 2006, International journal of cancer.

[71]  T. P. Pretlow,et al.  15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis , 2006, Proceedings of the National Academy of Sciences.

[72]  Jun Sun,et al.  Increased NF-κB activity in fibroblasts lacking the vitamin D receptor , 2006 .

[73]  B. Karlan,et al.  15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. , 2006, Cancer research.

[74]  E. Crawford,et al.  A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone‐refractory prostate cancer , 2006, Cancer.

[75]  A. Muñoz,et al.  Effects of 1α,25-Dihydroxyvitamin D3 in Human Colon Cancer Cells , 2006 .

[76]  H. Koeffler,et al.  Vitamin D compounds: activity against microbes and cancer. , 2006, Anticancer research.

[77]  F. Sinicrope Targeting cyclooxygenase‐2 for prevention and therapy of colorectal cancer , 2006, Molecular carcinogenesis.

[78]  D. Trump,et al.  Phase II trial of high‐dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen‐independent prostate cancer , 2006, Cancer.

[79]  L. Davis,et al.  RNA interference–mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor , 2006, Molecular Cancer Therapeutics.

[80]  D. Peehl,et al.  Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. , 2006, Cancer research.

[81]  Glenville Jones,et al.  Promise of vitamin D analogues in the treatment of hyperproliferative conditions , 2006, Molecular Cancer Therapeutics.

[82]  John Robbins,et al.  Calcium plus vitamin D supplementation and the risk of colorectal cancer. , 2006, The New England journal of medicine.

[83]  Martin Lipkin,et al.  The role of vitamin D in cancer prevention. , 2006, American journal of public health.

[84]  F. Sellke,et al.  Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. , 2006, Cardiovascular research.

[85]  C. Garland,et al.  Do sunlight and vitamin D reduce the likelihood of colon cancer? , 1980, International journal of epidemiology.

[86]  A. Muñoz,et al.  Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. , 2006, Anticancer research.

[87]  A. Douvdevani,et al.  Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[88]  Xianquan Zhan,et al.  Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. , 2005, Cancer research.

[89]  A. Llombart‐Bosch,et al.  Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. , 2005, European urology.

[90]  Laurent Lessard,et al.  Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study , 2005, British Journal of Cancer.

[91]  H. Koeffler,et al.  Vitamin D compounds in leukemia , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[92]  D. Peehl,et al.  Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity , 2005, Molecular and Cellular Endocrinology.

[93]  David Feldman,et al.  Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. , 2005, Cancer research.

[94]  N. Weigel,et al.  Androgen receptor signaling and vitamin D receptor action in prostate cancer cells , 2005, The Prostate.

[95]  S. Nagpal,et al.  Noncalcemic actions of vitamin D receptor ligands. , 2005, Endocrine reviews.

[96]  Marin L. Gantner,et al.  Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. , 2005, Biochemical and biophysical research communications.

[97]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[98]  C. Shapiro,et al.  Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. , 2005, The Journal of clinical endocrinology and metabolism.

[99]  A. Bergh,et al.  Cyclooxygenase-2 Expression Correlates with Local Chronic Inflammation and Tumor Neovascularization in Human Prostate Cancer , 2005, Clinical Cancer Research.

[100]  P. Lønning,et al.  Aromatase Inhibition: Translation into a Successful Therapeutic Approach , 2005, Clinical Cancer Research.

[101]  A. Muñoz,et al.  SNAIL vs vitamin D receptor expression in colon cancer: therapeutics implications , 2005, British Journal of Cancer.

[102]  R. Vieth,et al.  Pilot Study: Potential Role of Vitamin D (Cholecalciferol) in Patients With PSA Relapse After Definitive Therapy , 2005, Nutrition and cancer.

[103]  M. Hewison CHAPTER 79 – Extra-renal 1α-Hydroxylase Activity and Human Disease , 2005 .

[104]  K. Colston CHAPTER 93 – Vitamin D and Breast Cancer , 2005 .

[105]  H. Cross CHAPTER 95 – Vitamin D and Colon Cancer , 2005 .

[106]  J. O'kelly CHAPTER 96 – Vitamin D and Hematological Malignancy , 2005 .

[107]  A. Krishnan CHAPTER 94 – Vitamin D and Prostate Cancer , 2005 .

[108]  Edward Giovannucci,et al.  The epidemiology of vitamin D and cancer incidence and mortality: A review (United States) , 2005, Cancer Causes & Control.

[109]  J. Lutterbaugh,et al.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[110]  J. Welsh Vitamin D and breast cancer: insights from animal models. , 2004, The American journal of clinical nutrition.

[111]  V. Go,et al.  Vitamin D and colon carcinogenesis. , 2004, The Journal of nutrition.

[112]  W. Isaacs,et al.  Cyclooxygenases in cancer: progress and perspective. , 2004, Cancer letters.

[113]  J. Brooks,et al.  Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[114]  A. Bergh,et al.  Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase‐2, Bcl‐2, and cell proliferation in the glandular epithelium , 2004, The Prostate.

[115]  S. Itzkowitz,et al.  Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[116]  P. Malloy,et al.  Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. , 2004, Molecular endocrinology.

[117]  J. Lewin,et al.  Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.

[118]  T. Beer,et al.  Calcitriol in cancer treatment: from the lab to the clinic. , 2004, Molecular cancer therapeutics.

[119]  L. Lessard,et al.  Expression of NF‐κB in prostate cancer lymph node metastases , 2004 .

[120]  M. Lucia,et al.  Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. , 2004, The Journal of urology.

[121]  N. Bundred,et al.  COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ , 2004, British Journal of Cancer.

[122]  A. Rabson,et al.  NF‐κB activation in human prostate cancer: Important mediator or epiphenomenon? , 2004 .

[123]  F. Sinicrope,et al.  Role of cyclooxygenase-2 in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[124]  E. Yang,et al.  Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the Cytoplasm* , 2003, Journal of Biological Chemistry.

[125]  A. Giaccia,et al.  HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.

[126]  T. Yanase,et al.  Aromatase in bone: roles of Vitamin D3 and androgens , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[127]  G. Luo,et al.  Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation , 2003, Oncogene.

[128]  Yuan‐Chang Chung,et al.  Serum interleukin‐6 levels reflect the disease status of colorectal cancer , 2003, Journal of surgical oncology.

[129]  Kyucheol Cho,et al.  Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways , 2003, Oncogene.

[130]  Kelly Smith,et al.  Vitamin D-3 receptor as a target for breast cancer prevention. , 2003, The Journal of nutrition.

[131]  W. Weichert,et al.  Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma , 2003, Cancer.

[132]  G. Semenza,et al.  Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. , 2003, Cancer research.

[133]  H. Mukhtar,et al.  Cyclooxygenase-2 and prostate carcinogenesis. , 2003, Cancer letters.

[134]  T. Beer,et al.  High‐dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma , 2003, Cancer.

[135]  M. Holick,et al.  Prostatic 25‐hydroxyvitamin D‐1α‐hydroxylase and its implication in prostate cancer , 2003, Journal of cellular biochemistry.

[136]  T. Stamey,et al.  Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[137]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[138]  J. Welsh,et al.  Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[139]  D. Peehl,et al.  Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. , 2002, The Journal of urology.

[140]  G. Åkerström,et al.  25-hydroxyvitamin D3-1α-hydroxylase expression in normal and pathological parathyroid glands , 2002 .

[141]  L. Norton,et al.  Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer , 2002, The Journal of Biological Chemistry.

[142]  Andrew Dannenberg,et al.  COX-2 in cancer--a player that's defining the rules. , 2002, Journal of the National Cancer Institute.

[143]  P. Adegboyega,et al.  Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. , 2002, American journal of physiology. Cell physiology.

[144]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[145]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[146]  D. Heber,et al.  1α, 25-(OH)2-D3 and its synthetic analogue decrease tumor load in the Apcmin mouse , 2002 .

[147]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[148]  W. Boon,et al.  Aromatase--a brief overview. , 2002, Annual review of physiology.

[149]  Edgar M Moran,et al.  Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. , 2002, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[150]  W. Isaacs,et al.  Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. , 2001, Cancer Research.

[151]  M. A. Blankenstein,et al.  Aromatase and COX-2 expression in human breast cancers , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[152]  S. Catz,et al.  Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer , 2001, Oncogene.

[153]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[154]  J. Masferrer,et al.  Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. , 2001, Scandinavian journal of gastroenterology.

[155]  J. Bartek,et al.  Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. , 2001, Molecular endocrinology.

[156]  H. Cross,et al.  25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. , 2001, Biochemical and biophysical research communications.

[157]  P. Cohen,et al.  Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. , 2001, The Journal of urology.

[158]  H. Müller,et al.  Germline alterations in the cyclooxygenase‐2 gene are not associated with the development of extracolonic manifestations in a large Swiss familial adenomatous polyposis kindred , 2000, International journal of cancer.

[159]  N. Bundred,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo , 2000 .

[160]  D. Feldman,et al.  1α,25-Dihydroxyvitamin D3 Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells , 2000 .

[161]  T. Hla,et al.  Expression of cyclooxygenase‐2 in prostate carcinoma , 2000, Cancer.

[162]  L. G. García Rodríguez,et al.  Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. , 2000, Epidemiology.

[163]  Y. Chen,et al.  Prostaglandin E 2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells , 2000, British Journal of Cancer.

[164]  C. M. Hansen,et al.  Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. , 2000, Current pharmaceutical design.

[165]  C. Paraskeva,et al.  Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. , 2000, Cancer research.

[166]  A. Hoeflich,et al.  Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. , 2000, Cancer letters.

[167]  C. Bonifer,et al.  Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. , 2000, The American journal of pathology.

[168]  D. Bostwick,et al.  Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma , 2000, The Prostate.

[169]  Randall Harris,et al.  Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. , 2000, Oncology reports.

[170]  T. McDonnell,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-2* , 1999 .

[171]  M. Martin,et al.  Regulation of estrogen receptor‐α gene expression by 1,25‐dihydroxyvitamin D in MCF‐7 cells , 1999 .

[172]  C. N. Coleman,et al.  Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen , 1999, Oncogene.

[173]  D. Zhou,et al.  Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene. , 1999, Archives of biochemistry and biophysics.

[174]  A. Kato,et al.  High expression of cyclooxygenase‐2 in macrophages of human colonic adenoma , 1999, International journal of cancer.

[175]  F. Robertson,et al.  Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. , 1999, Cancer letters.

[176]  N. Weigel,et al.  Vitamin D and Prostate Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[177]  D. Feldman,et al.  Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity. , 1999, Endocrinology.

[178]  D. Heitjan,et al.  Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. , 1999, Urology.

[179]  D. Peehl,et al.  Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. , 1999, Endocrinology.

[180]  Z. Kmietowicz Patients with bone metastases need better care , 1998 .

[181]  M. Uskoković,et al.  Growth inhibitory effects of 1,25-dihydroxyvitamin D3 and its synthetic analogue, 1alpha,25-dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor-cholecalcifero l (Ro 25-6760), on a human colon cancer xenograft. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[182]  B. Wolff,et al.  1α,25‐Dihydroxyvitamin D3 decreases DNA binding of nuclear factor‐κB in human fibroblasts , 1998 .

[183]  R. Coombes,et al.  A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. , 1998, British Journal of Cancer.

[184]  T. Stamey,et al.  Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) , 1998, The Journal of urology.

[185]  T. Chen,et al.  Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[186]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[187]  V. Laudone,et al.  Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. , 1998, Urology.

[188]  D. Peehl,et al.  1α,25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-Dependent. , 1997, Endocrinology.

[189]  N. Weigel,et al.  1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. , 1997, Endocrinology.

[190]  M. Hughes-Fulford,et al.  Up-regulation of cyclooxygenase-2 by product-prostaglandin E2. , 1997, Advances in experimental medicine and biology.

[191]  C. Mendelson,et al.  Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. , 1996, Endocrinology.

[192]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[193]  H. Tazaki,et al.  Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. , 1996, Biochemical and biophysical research communications.

[194]  S Majewski,et al.  Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. , 1996, The journal of investigative dermatology. Symposium proceedings.

[195]  L. Freedman,et al.  Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. , 1996, Genes & development.

[196]  S. Manolagas,et al.  Erratum: Down-regulation of NF-κB protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3 (Proceedings of the National Academy of Sciences of the United States of America (November 21, 1995) 24 (524)) , 1996 .

[197]  S. Manolagas,et al.  Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[198]  G. Miller,et al.  Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[199]  E. Corder,et al.  Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[200]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[201]  L. Binderup,et al.  Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. , 1994, The Journal of endocrinology.

[202]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[203]  G. Schwartz,et al.  Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.

[204]  P. Reitsma,et al.  Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite , 1983, Nature.

[205]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.